2008
A Randomized, Double-Blind, Placebo-Controlled Tolerability Study of Intramuscular Aripiprazole in Acutely Agitated Patients With Alzheimer's, Vascular, or Mixed Dementia
Rappaport S, Marcus R, Manos G, McQuade R, Oren D. A Randomized, Double-Blind, Placebo-Controlled Tolerability Study of Intramuscular Aripiprazole in Acutely Agitated Patients With Alzheimer's, Vascular, or Mixed Dementia. Journal Of The American Medical Directors Association 2008, 10: 21-27. PMID: 19111849, DOI: 10.1016/j.jamda.2008.06.006.Peer-Reviewed Original ResearchConceptsAgitation-Calmness Evaluation ScaleIM aripiprazoleIM placeboMixed dementiaIntramuscular aripiprazoleDoses 2 hoursIncidence of oversedationTreatment of agitationHealthcare facilitiesPreliminary efficacy analysisAdverse event reportingNegative Syndrome ScaleLong-term careAcute agitationEfficacy analysisTolerability studyPlaceboPEC scoresAripiprazoleGreater incidenceSyndrome ScaleGreater efficacyPatientsVital signsDementia
2007
Efficacy and Safety of Oral Aripiprazole Compared with Haloperidol in Patients Transitioning from Acute Treatment with Intramuscular Formulations
DANIEL D, CURRIER G, ZIMBROFF D, ALLEN M, OREN D, MANOS G, MCQUADE R, PIKALOV A, CRANDALL D. Efficacy and Safety of Oral Aripiprazole Compared with Haloperidol in Patients Transitioning from Acute Treatment with Intramuscular Formulations. Journal Of Psychiatric Practice 2007, 13: 170-177. PMID: 17522560, DOI: 10.1097/01.pra.0000271658.86845.81.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdministration, OralAdolescentAdultAgedAntipsychotic AgentsAripiprazoleDouble-Blind MethodDyskinesia, Drug-InducedFemaleHaloperidolHumansInjections, IntramuscularMaleMiddle AgedPiperazinesPsychiatric Status Rating ScalesPsychomotor AgitationPsychotic DisordersQuinolonesSchizophreniaConceptsOral aripiprazoleOral formulationHaloperidol IMOral phaseIntramuscular formulationEfficacy measuresSchizoaffective disorderExtrapyramidal symptom-related adverse eventsPrimary efficacy measureStudy days 1Negative Syndrome ScalePlacebo IMAcute treatmentAdverse eventsGood tolerabilityClinical statusMean changePEC scoresPatientsDay 1HaloperidolAripiprazoleSyndrome ScaleInitial benefitComponent scores